Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Downgraded by Zacks Research to “Strong Sell”

Zacks Research cut shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from a hold rating to a strong sell rating in a report published on Tuesday,Zacks.com reports.

Several other analysts have also recently commented on the company. UBS Group upgraded Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, March 16th. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. DZ Bank cut shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a research note on Wednesday, February 18th. Barclays raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 6th. Finally, JPMorgan Chase & Co. raised shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Bayer Aktiengesellschaft Trading Up 0.7%

BAYRY stock opened at $10.98 on Tuesday. Bayer Aktiengesellschaft has a 12-month low of $5.30 and a 12-month high of $14.85. The business’s 50-day moving average is $12.43 and its 200 day moving average is $10.18. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10. The stock has a market cap of $43.15 billion, a price-to-earnings ratio of -9.89 and a beta of 0.69.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its earnings results on Wednesday, March 4th. The company reported $0.18 EPS for the quarter, meeting analysts’ consensus estimates of $0.18. The business had revenue of $13.24 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Bayer Aktiengesellschaft had a positive return on equity of 15.35% and a negative net margin of 8.51%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. On average, sell-side analysts anticipate that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.